focus -WSS

focus

author：entertainment 2025-09-28 02:29:58 - browse：512

Adobe

WASHINGTON — The federal government increasingly is scrutinizing Chinese businesses and their interactions with American companies, including in the biotech sector. Chinese biotechnology companies, the thinking goes, could threaten national security by giving the Chinese government access to the genetic and health information of Americans.

Just Wednesday, President Biden issued an executive order aimed at keeping sensitive data, including Americans’ genetic information, out of the hands of adversaries.

But American biotech companies worry they could become collateral damage if the government sloppily targets sanctions. They’re pushing back against legislation that would bar biotech companies from working with some Chinese companies, especially as the government takes aim at WuXi, a Chinese company considered a crucial partner for discovering, testing, and making medicines that has worked with such brands as Pfizer, AstraZeneca, and GSK.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Christmas in the PICU brings some surprising joy

WSS

Virtual care provider acquires bankrupt Pear's prescription apps

Why health records don't always know when patients are dead

Grail spinoff by Illumina should end disastrous merger attempt

Editas, Vertex strike deal on CRISPR

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Texas board proposes rules on abortion law emergency exemption

focus

focus

hotspot

Affirmative action in medical school literally saved lives

Texas board proposes rules on abortion law emergency exemption

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Tori Bowie and the unacceptable rates of Black maternal death

Medicare Advantage beneficiaries sue Humana over algorithm use

BioMarin wins approval for gene therapy to treat hemophilia A

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

What Kate Middleton's cancer revelation might teach the world

focus

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Virtual care provider acquires bankrupt Pear's prescription apps

Pfizer, Moderna say biotech, pharma drug development is a sprint

Hospitals owned by private equity see complications spike 25%

Readout Newsletter: Illumina, CRISPR, Regeneron

'Patient friction coefficient' can gauge a clinical trial's patient burden

entertainment

focus

focus

focus